Cargando…

Local Consolidative Therapy for Oligometastatic Non-Small Cell Lung Cancer

SIMPLE SUMMARY: Metastatic non-small cell lung cancer (NSCLC) classically portends a poor prognosis and worse overall survival. However, recent advances in modern systemic therapy and the increasing recognition of a distant clinical entity known as “oligometastatic disease”—i.e., a controlled primar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santos, Patricia Mae G., Li, Xingzhe, Gomez, Daniel R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406686/ https://www.ncbi.nlm.nih.gov/pubmed/36010969 http://dx.doi.org/10.3390/cancers14163977

Ejemplares similares

Local therapy treatment conditions for oligometastatic non-small cell lung cancer
por: Zhang, Suli, et al.
Publicado: (2022)

Local consolidative therapy for synchronous oligometastatic non‐small cell lung cancer treated with first‐line pembrolizumab: A retrospective observational study
por: Chen, Ya, et al.
Publicado: (2022)

Results of Radiation Therapy as Local Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer
por: Billing, David L., et al.
Publicado: (2021)

Local ablative radiotherapy for oligometastatic non-small cell lung cancer
por: Suh, Yang-Gun, et al.
Publicado: (2019)

Oligometastatic non-small cell lung cancer: Current management
por: Román-Jobacho, Alicia, et al.
Publicado: (2021)

Management of Synchronous Extrathoracic Oligometastatic Non-Small Cell Lung Cancer
por: Jones, Gregory D., et al.
Publicado: (2021)

Classifying Oligometastatic Non-Small Cell Lung Cancer
por: Blumenthaler, Alisa N., et al.
Publicado: (2021)

First-Line Tyrosine Kinase Inhibitors Combined With Local Consolidative Radiation Therapy for Elderly Patients With Oligometastatic Non-Small Cell Lung Cancer Harboring EGFR Activating Mutations
por: Hu, Xiaolong, et al.
Publicado: (2022)

Evaluating single-institution resource costs of consolidative radiotherapy for oligometastatic non-small cell lung cancer using time-driven activity-based costing
por: Pezzi, Todd A., et al.
Publicado: (2020)

Patient Selection for Local Aggressive Treatment in Oligometastatic Non-Small Cell Lung Cancer
por: Werner, Raphael S., et al.
Publicado: (2021)

The Role of Surgery for Oligometastatic Non-Small Cell Lung Cancer
por: Euhus, Caleb J., et al.
Publicado: (2022)

Oligometastatic Disease in Non-Small-Cell Lung Cancer: An Update
por: Chen, Yi-Hsing, et al.
Publicado: (2022)

Local Consolidative Therapy versus Maintenance Therapy/Observation for Patients with Oligometastatic Non-Small Cell Lung Cancer without Progression after Front-Line Systemic Therapy: Results of a Multi-Institutional Phase II Randomized Study
por: Gomez, Daniel R., et al.
Publicado: (2016)

Successful continuous nivolumab therapy for metastatic non‐small cell lung cancer after local treatment of oligometastatic lesions
por: Tobita, Satoshi, et al.
Publicado: (2020)

Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer
por: Tibdewal, Anil, et al.
Publicado: (2021)

Oligometastatic non-small-cell lung cancer: current treatment strategies
por: Richard, Patrick J, et al.
Publicado: (2016)

Current treatment landscape for oligometastatic non-small cell lung cancer
por: Garde-Noguera, Javier, et al.
Publicado: (2022)

Role of local ablative treatment in oligometastatic non-small cell lung cancer: a meta-analysis
por: Rim, Chai Hong, et al.
Publicado: (2023)

Standard maintenance therapy versus local consolidative radiation therapy and standard maintenance therapy in 1–5 sites of oligometastatic non-small cell lung cancer: a study protocol of phase III randomised controlled trial
por: Tibdewal, Anil, et al.
Publicado: (2021)

Evaluation of local aggressive lung therapy versus systemic therapy in oligometastatic non-small cell lung cancer: a systematic review and meta-analysis
por: Zhang, Chenxi, et al.
Publicado: (2021)

Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy
por: Bai, Hao, et al.
Publicado: (2016)

Local treatment of synchronous oligometastatic non-small cell lung cancer (NSCLC)—current consensus and future perspectives
por: Almeldin, Doaa Said, et al.
Publicado: (2020)

Clinical outcome of node‐negative oligometastatic non–small cell lung cancer
por: Sakai, Kiyohiro, et al.
Publicado: (2016)

Stereotactic Body Radiotherapy for Oligometastatic Disease in Non-small Cell Lung Cancer
por: Wujanto, Caryn, et al.
Publicado: (2019)

Oligometastatic non-small cell lung cancer: from biology to clinical practice
por: Infante, Maurizio V., et al.
Publicado: (2021)

Radiotherapy for oligometastatic non-small cell lung cancer: a narrative review
por: Sundahl, Nora, et al.
Publicado: (2021)

Local ablative therapy in oncogenic-driven oligometastatic non-small cell lung cancer: present and ongoing strategies—a narrative review
por: Fallet, Vincent, et al.
Publicado: (2021)

The value of local consolidative therapy in Osimertinib-treated non-small cell lung cancer with oligo-residual disease
por: Zeng, Ya, et al.
Publicado: (2020)

Lobectomy Can Improve the Survival of Patients With Non-small Cell Lung Cancer With Lung Oligometastatic
por: Wang, Lingwei, et al.
Publicado: (2021)

Narrative review: molecular and genetic profiling of oligometastatic non-small cell lung cancer
por: Rashdan, Sawsan, et al.
Publicado: (2021)

The Effect of immunotherapy on oligometastatic non-small cell lung cancer patients by sites of metastasis
por: Ma, Jia-Chun, et al.
Publicado: (2022)

Oligometastatic Non-Small Cell Lung Cancer: A Practical Review of Prospective Trials
por: Baydoun, Atallah, et al.
Publicado: (2022)

Genomic Characteristics and the Potential Clinical Implications in Oligometastatic Non–Small Cell Lung Cancer
por: Liao, Rongxin, et al.
Publicado: (2023)

Osimertinib as induction therapy for oligometastatic non-small cell lung cancer with EGFR mutation: a case report
por: Wu, Han, et al.
Publicado: (2022)

Oligometastatic Disease at Presentation or Recurrence for Nonsmall Cell Lung Cancer
por: Gomez, Daniel R., et al.
Publicado: (2012)

Treatment patterns and survival after 18F-fluorodeoxyglucose positron emission tomography/computed tomography-guided local consolidation therapy for oligometastatic non-small cell lung cancer: a two-center propensity score-matched analysis
por: Song, Ying-Qiu, et al.
Publicado: (2020)

Real-world multicentre analysis of neoadjuvant immunotherapy and chemotherapy in localized or oligometastatic non-small cell lung cancer (KOMPASSneoOP)
por: Faehling, Martin, et al.
Publicado: (2022)

A Call for the Aggressive Treatment of Oligometastatic and Oligo-Recurrent Non-Small Cell Lung Cancer
por: Patel, Pretesh R., et al.
Publicado: (2012)

Stereotactic body radiotherapy improves the survival of patients with oligometastatic non‐small cell lung cancer
por: Ouyang, Wen, et al.
Publicado: (2019)

Radiotherapy for oligometastatic tumor improved the prognosis of patients with non‐small cell lung cancer (NSCLC)
por: Gong, Hong‐yun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ca8dfo84j07dufvhkk9elpu7id